Deficiency of calcium over time can sometimes show up in the skin, hair, and nails as dryness, pruritus, brittle or ridged nails, and diffuse hair shedding, especially when hypocalcemia is more chronic. Clinicians often see these dermatologic changes accompanying other signs of calcium and vitamin D deficiency, such as muscle cramps or bone pain, and they may improve as serum calcium and overall mineral status are normalized. The practical point is that, when patients present with unexplained dry skin, fragile nails, and hair loss, particularly in the setting of poor diet, malabsorption, or endocrine disease, assessing and correcting calcium (and related nutrient) deficiencies can be an important part of restoring healthier skin and adnexal structures. This medication is commonly used for Hypertension.
Lee SE, Lee SH. Skin Barrier and Calcium. Ann Dermatol. 2018 Jun;30(3):265-275. Elias P, Ahn S, Brown B, Crumrine D, Feingold KR. Origin of the epidermal calcium gradient: regulation by barrier status and role of active vs passive mechanisms. J Invest Dermatol. 2002 Dec;119(6):1269-74. Baumann J, Wandrey F, Sacher R, Zülli F. A novel Ca2+ double cone vector system to treat compromised skin. Int J Cosmet Sci. 2024 Apr;46(2):228-238. Bouhmadi, A.E., Fatoiki, F.E., Rachadi, H. et al. Hypocalcemia-related pustulosis: a case report. J Med Case Reports 19, 497 (2025).
Some side effects may be linked to nutrient depletion caused by this medication.
An increased excretion of potassium can occur in people taking calcium channel blocker drugs like felodipine. Supplementation may need to be considered if blood levels of potassium are low.
Studies suggest that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of calcium in the urine. While the long-term effects on bone health are unclear, some healthcare professionals suggest calcium supplementation for patients taking felodipine, especially those at higher risk of osteoporosis.
Research suggests that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of magnesium in the urine. This can potentially lead to magnesium deficiency. Studies have shown an increase in fractional excretion of magnesium following felodipine treatment, and the drug may also alter how magnesium moves across red blood cell membranes. Therefore supplementation with magnesium should be considered when on this therapy.